CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 91 enrolled
Drug / intervention
Vinorelbine plus Epirubicin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02628613
NCT02628613Phase 2Completed
CompareCT.gov

Phase II Randomized Clinical Trial and Biomarker Analysis of Paclitaxel Plus Epirubicin Versus Vinorelbine Plus Epirubicin as Neoadjuvant Chemotherapy in Locally Advanced HER2-Negative Breast Cancer With TEKT4 Variations

Fudan University·interventional·Posted Dec 11, 2015·Updated Nov 1, 2019

In Brief

A Phase 2 clinical trial evaluating Vinorelbine plus Epirubicin and Paclitaxel plus Epirubicin for Breast Cancer. Completed, enrolled 91 participants across 1 site.

Detailed Summary

The purpose of this study is to compare the efficiency and safety between paclitaxel combined with epirubicin and vinorelbine combined with epirubicin when used in neoadjuvant chemotherapy for locally advanced (IIb-IIIc) HER2-negative breast cancer with TEKT4 variations.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesChina
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 11, 2015
Enrollment StartDec 1, 2015
Primary CompletionFeb 1, 2019
TodayJul 1, 2026
Enrollment to primary: 3.2 yearsPosted 10.6 years ago

Interventions

Vinorelbine plus Epirubicindrug

Evaluate the efficiency and safety of vinorelbine plus epirubicin as neoadjuvant chemotherapy in locally advanced HER2-negative breast cancer with TEKT4 variations

Paclitaxel plus Epirubicindrug

standard neoadjuvant chemotherapy